The Pro-curo fortnightly briefing. Every two weeks we pick the stories that matter to people who look after samples and explain what they mean in practice, with a link to every source.
The MHRA's GCP guidance names laboratories analysing clinical trial samples among the organisations that must comply, so its trial master file and dossier expectations reach sample teams as well as sponsors.
The HTA ran 226 planned regulatory assessments in 2025/26 and kept two-person unannounced inspections in the post-mortem sector because of ongoing high levels of risk, incidents and shortfalls.
One email every two weeks with the issue, the sources and nothing else. Unsubscribe with one click. We only add people who have asked to hear from us.
A six-minute tour of Version 5, or a conversation with Rhys, our AI assistant, whenever suits you.
